FORMULATION DEVELOPMENT AND EVALUATION OF DOXORUBICIN HYDROCHLORIDE LIPOSOMES
Pathan Shabana*, Sasikanth Kothamasu and Manohar Babu S.
ABSTRACT
The main objective of this work was designed to prepare and evaluate the Doxorubicin HCl Liposomes with a controlled release upto 15 days. This formulation (MVL) will prolong the release of drug and reduce the side effects by non-PEGylated formulation. The Liposomes were prepared by Double Emulsion methods which form Multivesicular liposomes which show better controlled release. The Particle size, Entrapment efficiency, drug loading were optimized and ideal formulation (F3) was obtained. Liposomes were stored at 4°C and given for further evaluation. The prepared Liposomes of F2, F4 and F6 formulations were evaluated for physical and chemical characteristics like average vesicle size, shape and zeta potential. The evaluated batches showed good physicochemical characteristics in F3
formulation when compared to the F2 and F4 formulations. The prepared Liposomes of F1 to F6 were evaluated for % free drug and Assay, the % Free drug was optimum in F3 formulation when compared to other formulations of F1, F2, F4 , F5 and F6. The Assay was optimum in F3 formulation when compared to other formulations of F1, F2, F4, F5 and F6. This developed liposomal drug delivery system was also evaluated for drug release in pH 7.4 phosphate buffer using membrane diffusion method. The release of drug from F3 formulation was found to be sustained to certain extent when compared to F1, F2, F4, F5 and F6 formulations.
Keywords: Doxorubicin HCl, Multivesicular liposomes (MVL), Entrapment efficiency.
[Download Article]
[Download Certifiate]